HDAC3 and small cell lung carcinoma: Considering for the increased susceptibility of SCLC-N cells to the killing of NK cells by both c-Myc inhibitor and HDAC inhibitor, we speculated that the application of HDAC inhibitor, especially HDAC3 inhibitor, might be an effective immunotherapy strategy targeting innate immunity for MYC-amplificated SCLC-N and could solve the problem that c-Myc is largely unstructured, falling in the category of ontrinsically disordered proteins [43] and is difficult to be targeted by small molecule inhibitors.